Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023467 (
acute myeloid leukemia
)
35,200
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Granulocyte colony-stimulating factor (G-CSF) can elicit responses that include proliferation, granulocytic differentiation, and activation of cellular functions in target cells. The biochemical pathways responsible for transduction of these signals from the G-CSF receptor (G-CSFR) have not been defined. In this report, we show that, in murine (NFS-60) and human (OCI-
AML
1) myeloid leukemia cell lines and in murine pro-B-lymphocytic cells, BAF/B03, transfected with the murine G-CSFR, proliferative responses to G-CSF are associated with rapid activation of p42 and p44 MAP kinases and p21ras. Truncation of the cytoplasmic portion of the murine G-CSFR at residue 646 but not at residue 739 abolished G-CSF-induced stimulation of cellular proliferation as well as activation of
MAP kinase
and p21ras in transfected BAF/B03 cells. G-CSF-induced granulocytic differentiation of the murine leukemic cell line 32DC13(G) occurred in the absence of detectable activation of p42
MAP kinase
. Nonproliferative responses to G-CSF in the human promyelocytic cell line HL-60 and in human neutrophils were similarly associated with no
MAP kinase
activation. These results imply that differing cellular effects of G-CSF may be involve the recruitment of differing signal transduction pathways with the p21ras/
MAP kinase
pathway being limited to proliferative responses.
...
PMID:Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathway. 750 13
The myelomonocytic lineage of hematopoiesis is regulated by the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF). This cytokine has proven to be safe for use in coordination with the treatments for bone marrow transplants and
acute myelogenous leukemia
. GM-CSF and related cytokines operate through specific receptors in the membranes of target cells of the myelopoietic lineages (both immature and mature cells). The exact signal transduction mechanisms in the cell are only beginning to be clarified and involve a plethora of signaling molecules. With a wealth of new information from studies in GM-CSF-induced cell activation, three major experimental approaches are emerging as gold standards in the exploration of those signaling pathways initiated by hematopoietic growth factors. We consider here: (1) a protein-protein interaction, as exemplified by the association between the cytokine membrane receptor and JAK kinase; (2) a covalent modification of an enzyme, as studied in the phosphorylation of
MAP kinase
; and (3) a protein-DNA interaction, as demonstrated by the translocation of STAT from the cytosol to the nucleus where it can bind to the promoters of specific genes.
...
PMID:Emerging paradigms in granulocyte-macrophage colony-stimulating factor signaling. 895 Mar 14
Mitogen-activated protein (MAP) kinase appears to be one of the key regulators of cell proliferation and differentiation. Very little, however, has been revealed as to how
MAP kinase
is involved in leukemogenesis. We have studied the activation of the
MAP kinase
pathway in 100 human primary leukemia cells including 73 acute myelogenous leukemias (AMLs). Forty acute leukemia samples (40% of the total), including 37
AML
samples (51% of
AML
), showed activation of
MAP kinase
as revealed by the mobility shift of the phosphorylated form of the protein and by in vitro kinase assay. This activation was correlated with MAP kinase kinase activity in these cells. In contrast, none of 14 chronic myelogenous leukemia samples showed the activation of
MAP kinase
. These results suggest that the
MAP kinase
pathway is constitutively activated in a subset of primary acute leukemias, and thus indicate the possible role of the constitutively activated
MAP kinase
in leukemogenesis.
...
PMID:Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. 909 86
We investigated tyrosine phosphorylation of proteins in primary human leukemia cells stimulated by granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), interleukin-3 (IL-3), tumor necrosis factor (TNF), thrombopoietin (TPO) and phorbol myristate acetate (PMA) in 61 patients with
acute myeloid leukemia
(
AML
), nine patients with chronic myeloid leukemia (CML) in blastic crisis and four patients in chronic phase, and compared these data of leukemia with those of normal human immature hematopoietic cells. These cytokines and PMA induced tyrosine phosphorylation of proteins in a manner characteristic for each cytokine or PMA in
AML
cells. G-CSF, GM-CSF and IL-3 frequently phosphorylated p92, p80, p70, p44 and p42. p95 was frequently phosphorylated by G-CSF, and was phosphorylated in one third of the cases by TPO. On the other hand, TNF selectively induced tyrosine phosphorylation of p42, and PMA selectively induced that of p44 and p42. In marked contrast to
AML
cells, CML cells responded poorly to cytokines with protein tyrosine phosphorylation, and normal human bone marrow mononuclear cells and CD34-positive cells also showed poor response to cytokines. The results of the immunoprecipitation studies showed tyrosine phosphorylation of signal transducers and activators of transcription (Stat) 5 induced by G-CSF, GM-CSF, IL-3 and/or TPO in six cases, that of
extracellular signal-regulated kinase
(
ERK
) by GM-CSF in two cases and that of p38 by TNF in three cases. Intracellular amount of Stat5 was markedly increased in
AML
cells compared with that in CML cells and normal human bone marrow cells. whereas intracellular amount of
ERK
and p38 was uniformly abundant in both leukemic and normal cells. These results show cytokine-specific and amplified tyrosine phosphorylation of proteins in
AML
cells and suggest that amplified response might, at least in part, result from the increased amount of signaling molecules such as Stat5.
...
PMID:Tyrosine phosphorylation of proteins in primary human myeloid leukemia cells stimulated by cytokines: analysis of the frequency of phosphorylation, and partial identification and semi-quantification of signaling molecules. 988 38
Mitogen-activated protein (MAP) kinases act as transducers of extracellular signaling via tyrosine kinase-growth factor receptors and G-protein-linked receptors to transcription factors. Constitutive activation of
MAP kinase
has been observed in a variety of solid tumors including renal cancer and breast cancer. Recently, we have reported that constitutively activated
MAP kinase
was observed in 50% of human primary
acute myeloid leukemia
(
AML
) cells. Ras is one of the components of G-proteins and transduces the signal from cytokine receptors to raf-1 theoretically resulting in the activation of
MAP kinase
pathway. In the present study, we have examined the correlation of Ras mutations and the activation of
MAP kinase
pathway in patients with
AML
. Twenty out of 22
AML
cases with activating N-Ras mutations showed no phosphorylated forms of
ERK2
.
ERK2
phosphorylation was tightly correlated with
ERK1
phosphorylation and
MAP kinase
activity detected by in vitro kinase assay. Three samples with N-Ras mutations were stimulated with IL-3, GM-CSF and G-CSF separately but
ERK2
activation was induced in none of these samples stimulated with these cytokines. In contrast,
ERK2
was constitutively activated in all of four pancreatic carcinoma cases with K-Ras mutation at codon 12. These results suggest that function of the Ras mutations may be different between solid tumors, such as pancreatic carcinoma and colorectal carcinoma, and
AML
. Mutated Ras does not always stimulate
MAP kinase
pathway constitutively and may rather inhibit classical
MAP kinase
cascade in
AML
blasts from leukemia patients.
...
PMID:Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation. 1021 65
We have recently identified an internal tandem duplication of the human Flt3 gene in approximately 20% of
acute myeloid leukemia
(
AML
) cases. In the present study, the wild-type and the mutant Flt3 genes were transfected into two IL-3-dependent cell lines, 32D and BA/F3 cells. Mutant Flt3-transfected cells exhibited autonomous growth while wild-type Flt3-transfected cells with the continuous stimulation of Flt3 ligand exhibited a minimal proliferation. Cells expressing mutant Flt3 showed constitutive activation of STAT5 and
MAP kinase
. In contrast, Flt3 ligand stimulation caused rapid activation of
MAP kinase
but not STAT5 in cells expressing wild-type Flt3. Finally, we found constitutive activation of
MAP kinase
and STAT5 in all clinical samples of
AML
patients with mutant Flt3. Our study shows the significance of internal tandem duplication of Flt3 receptors for leukemia cell expansion.
...
PMID:Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. 1069 7
HePTP is a tyrosine specific protein phosphatase that is strongly expressed in activated T-cells. It was recently demonstrated that in transfected T-cells HePTP impairs TCR-mediated activation of the MAP-kinase family members
ERK2
and p38 and it was suggested that both ERK and p38 MAP-kinases are substrates of HePTP. The HePTP gene has been mapped to human chromosome 1q32.1. Abnormalities in this region are frequently found in various hematopoietic malignancies. HePTP is highly expressed in
acute myeloid leukemia
and its expression in fibroblasts resulted in transformation. To address a possible involvement of HePTP in hematopoietic malignancies we sought to identify HePTP substrate(s) in leukemic cells. Using substrate trapping mutants we have identified the MAP-kinase
ERK2
as a specific target of HePTP in the myelogenous leukemia cell line K562. Tyrosine phosphorylated
ERK2
, but not
ERK1
, p38, or JNK1, efficiently bound to catalytically inactive HePTP mutants in which the active site cysteine (HePTP-C/S) or the conserved aspartic acid residue (HePTP-D/A) had been exchanged for serine and alanine, respectively. Moreover, the interaction of
ERK2
with HePTP trapping mutants was dependent on
ERK2
tyrosine phosphorylation, indicating that HePTP is specifically targeted to activated
ERK2
. Using a deletion mutant of HePTP (HePTP-dLD), in which 14 amino acid residues within the N-terminus are missing, we show that regions outside the catalytic domain are also required for the interaction. Furthermore, overexpression of HePTP in K562 cells and fibroblasts interfered with PMA or growth factor induced MAP-kinase activation and HePTP efficiently dephosphorylated active
ERK2
on the tyrosine residue in the activation loop in vitro. Together, these data identify
ERK2
as a specific and direct target of HePTP and are consistent with a model in which HePTP negatively regulates
ERK2
activity as part of a feedback mechanism. Oncogene (2000) 19, 858 - 869.
...
PMID:The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP. 1070 94
The TEL-TRKC fusion is expressed as a consequence of t(12;15)(p13;q25), and is associated with two human cancers: congenital fibrosarcoma and
acute myelogenous leukemia
(
AML
). We report that the T/T(F) and T/T(L) fusion variants associated with congenital fibrosarcoma and
AML
, respectively, are constitutively tyrosine phosphorylated, and confer factor-independent growth to the murine hematopoietic cell line Ba/F3. Retroviral transduction of T/T(L) causes a rapidly fatal myeloproliferative disease in a murine bone marrow transplant (BMT) model, whereas T/T(F) causes a long-latency, pre-B-cell lymphoblastic lymphoma. TEL-TRKC variants are potent activators of the
MAP kinase
pathway, but neither variant activates Stat5 or other Stat family members. T/T(L), but not T/T(F), induces tyrosine phosphorylation of phospholipase Cgamma (PLCgamma), phosphoinositol-3 kinase and SHC. However, mutation analysis demonstrates that PLCgamma tyrosine phos phorylation by T/T(L) is dispensable for induction of the myeloproliferative phenotype by T/T(L). Collectively, these data demonstrate that the TEL-TRKC fusion variants are oncoproteins that activate the
MAP kinase
pathway, and do not require activation of either PLCgamma or Stat5 for efficient induction of a myeloproliferative phenotype in the murine BMT model.
...
PMID:Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. 1077 67
Recent studies suggest that the population of malignant cells found in human
acute myelogenous leukemia
(
AML
) arises from a rare population of leukemic stem cells (LSCs). LSCs have been documented for nearly all
AML
subtypes and have been phenotypically described as CD34+/CD38- or CD34+/HLA-DR-. Given the potentially critical role of these primitive cells in perpetuating leukemic disease, we sought to further investigate their molecular and cellular characteristics. Flow cytometric studies using primary
AML
tissue showed that the interleukin-3 receptor alpha chain (IL-3Ralpha or CD123) was strongly expressed in CD34+/CD38- cells (98 +/- 2% positive) from 16 of 18 primary specimens. Conversely, normal bone marrow derived CD34+/CD38- cells showed virtually no detectable expression of the CD123 antigen. To assess the functional role of IL-3Ralpha positive cells, purified CD34+/CD123+ leukemia cells were transplanted into immune deficient NOD/SCID mice. These experiments showed that CD123+ cells were competent to establish and maintain leukemic populations in vivo. To begin to elucidate a biological role for CD123 in leukemia, primary
AML
samples were analyzed with respect to signal transduction activity in the
MAPK
, Akt, and Stat5 pathways. Phosphorylation was not detected in response to IL-3 stimulation, thereby suggesting CD123 is not active in conventional IL-3-mediated signaling. Collectively, these data indicate that CD123 represents a unique marker for primitive leukemic stem cells. Given the strong expression of this receptor on LSCs, we propose that targeting of CD123 may be a promising strategy for the preferential ablation of
AML
cells.
...
PMID:The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. 1102 53
In this study, we utilized retroviral transfer of cDNA libraries in order to identify oncogenes that are expressed in
acute myeloid leukemia
(
AML
). From screens using two different cell types as targets for cellular transformation, a single cDNA encoding a variant of the TrkA protooncogene was isolated. The protein product of this protooncogene, TrkA, is a receptor tyrosine kinase for nerve growth factor. The isolated transforming cDNA encoded a TrkA protein that contains a 75-amino-acid deletion in the extracellular domain of the receptor and was named DeltaTrkA. DeltaTrkA readily transformed fibroblast and epithelial cell lines. The deletion resulted in activation of the tyrosine kinase domain leading to constitutive tyrosine phosphorylation of the protein. Expression of DeltaTrkA in cells led to the constitutive activation of intracellular signaling pathways that include Ras,
extracellular signal-regulated kinase
/
mitogen-activated protein kinase
, and Akt. Importantly, DeltaTrkA altered the apoptotic and growth properties of 32D myeloid progenitor cells, suggesting DeltaTrkA may have contributed to the development and/or maintenance of the myeloid leukemia from which it was isolated. Unlike Bcr-Abl, expression of DeltaTrkA did not activate Stat5 in these cells. We have detected expression of DeltaTrkA in the original
AML
sample by reverse transcriptase PCR and by Western blot analysis. While previous TrkA mutations identified from human tumors involved fusion to other proteins, this report is the initial demonstration that deletions within TrkA may play a role in human cancers. Finally, this report is the first to indicate mutations in TrkA may contribute to leukemogenesis.
...
PMID:Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. 1107 67
1
2
3
4
5
6
7
8
9
10
Next >>